Activation of JNK signaling has been confirmed to render chemotherapy resistance in a variety of malignancies, including hepatocellular carcinoma [40], gastric cancer [41], and pancreatic cancer [42]. This evidence concerns the gene MAPK8 and pancreatic neoplasm.